Rebound weight gain after stopping a GLP-1 is real, measurable, and faster than many patients expect. Two withdrawal trials, STEP 4 (semaglutide, published 2021) and SURMOUNT-4 (tirzepatide, published 2024), give us the clearest evidence available in 2026 for how much weight tends to return, how quickly, and what happens to the metabolic gains along with the weight. This article walks through what those trials showed, why rebound happens, the limits of what the evidence actually proves, and what to discuss with your prescriber before or after stopping.

If you are newer to the medication class, what GLP-1 medications are and how they work covers the basics. The evidence on stopping — the part below — is the piece most patients never hear in full at the pharmacy counter.

What Happens to Weight If You Stop a GLP-1?

The short answer: in the two major randomized withdrawal trials, adults who stopped semaglutide or tirzepatide regained a large share of their lead-in weight loss over roughly the next year, even with lifestyle counseling.

STEP 4 (semaglutide 2.4 mg, the Wegovy dose). In STEP 4 (Rubino et al., JAMA 2021), 803 adults with obesity or overweight took semaglutide 2.4 mg weekly for 20 weeks and lost an average of 10.6% of their body weight during that open-label lead-in. They were then randomized to continue semaglutide or switch to placebo for an additional 48 weeks, through week 68. By the end of the trial:

Adults who continued semaglutide lost an additional 7.9% on average, finishing at roughly 17.4% total weight loss from baseline.
Adults who switched to placebo regained an average of 6.9% of body weight, finishing at roughly 5.0% total weight loss from baseline.

The two groups diverged within weeks of the switch. By trial end, the placebo group's total loss from baseline (about 5.0%) was less than a third of what the continuation group had achieved (about 17.4%).

SURMOUNT-4 (tirzepatide, the Zepbound molecule). In SURMOUNT-4 (Aronne et al., JAMA 2024), 670 adults with obesity took tirzepatide at the maximum tolerated dose (10 or 15 mg weekly) for 36 weeks and lost an average of 20.9% of their body weight. They were then randomized to continue tirzepatide or switch to placebo for another 52 weeks, through week 88. By the end of the trial:

Adults who continued tirzepatide lost an additional 5.5% on average, finishing at roughly 25.3% total weight loss.
Adults who switched to placebo regained an average of 14.0% of body weight, finishing at roughly 9.9% total weight loss.

The absolute gap between continuing and stopping was about 15 percentage points of body weight — at a scale well beyond what lifestyle change alone produces in similar populations.

Put the two trials together, and the expected trajectory after stopping a modern GLP-1 without an effective replacement plan is substantial regain over the following year, though nearly every participant retained some of their original loss.

Why the Weight Comes Back

Weight regain after stopping a GLP-1 is not primarily a willpower story. It is a hormone and physiology story, broadly described in the obesity-medicine literature on weight maintenance after loss.

GLP-1 receptor agonists work by activating the GLP-1 receptor — and in tirzepatide's case, also the GIP receptor — producing three effects that together reduce how much a person eats:

Slower gastric emptying and a longer sense of fullness after meals
A central signal that turns down appetite drive
Steadier post-meal glucose, which reduces hypoglycemia-linked hunger

Stop the medication, and those signals fade as drug levels fall over days to weeks — semaglutide and tirzepatide both have long half-lives, so hunger and meal-size cues return gradually rather than abruptly. In parallel, the body that just lost 15–25% of its mass has a lower resting energy requirement than the larger body that preceded it — a shift sometimes called adaptive thermogenesis. The hormonal side of this adaptation is well documented: Sumithran and colleagues (NEJM, 2011) measured leptin, ghrelin, peptide YY, and other appetite-related peptides — along with self-reported hunger — and found the shift away from pre-weight-loss values persisted at least a year after non-medication weight loss. Stronger appetite pressure meeting lower caloric needs tends to produce weight gain until the two sides re-balance.

This is broadly the same dynamic that drives weight regain after dieting, bariatric surgery, and other obesity medications, though the rate and magnitude differ. GLP-1 withdrawal is distinctive mostly for how visible the regain can be in patients who started from a high weight loss.

Is Rebound Inevitable?

Not universally — but on average, participants in both STEP 4 and SURMOUNT-4 who stopped regained meaningful weight by trial end. Individual variation was substantial: some participants in the placebo arms retained most of their loss, others regained more than the average.

Factors that appear to moderate regain, based on the trial data and the broader obesity-medicine literature:

Baseline weight and the depth of prior loss. Participants who lost a smaller share tended to regain a smaller share.
Concurrent lifestyle support. All participants in STEP 4 and SURMOUNT-4 received reduced-calorie diet and physical-activity counseling, and regain still occurred on average. Lifestyle counseling alone does not neutralize the hormonal shift from medication withdrawal.
Lean-mass preservation. Rapid weight loss — with or without a GLP-1 — can include meaningful loss of lean mass. Patients who resistance-train and maintain adequate protein intake tend to retain more lean mass, though evidence that this specifically reduces post-withdrawal regain is limited.
Re-initiation of therapy. The trials did not study what happens if someone restarts a GLP-1 after regain. Clinical experience suggests the second course tends to produce directionally similar loss, but this has not been rigorously trialed.

What the evidence does not support is the claim that any specific diet, supplement, or structured program fully prevents regain after GLP-1 withdrawal in patients with obesity.

What These Trials Do Not Prove

Four caveats help interpret the numbers honestly.

The trial populations were specific. STEP 4 and SURMOUNT-4 both excluded adults with type 2 diabetes. The regain trajectory for adults with diabetes stopping a GLP-1 has been studied less formally, and the interaction with blood-sugar changes adds complexity that pure obesity trials do not capture.
Everyone received lifestyle counseling. Both trials supplied reduced-calorie diet and exercise counseling as standard of care. Real-world patients who stop a GLP-1 and also lose structured counseling may regain more than the trial averages suggest.
An average is not your outcome. A 14% average regain in SURMOUNT-4 reflects a distribution: some participants regained much more, some less. The trial cannot tell any one patient what their personal trajectory will be.
Neither trial tested a taper. Both used abrupt withdrawal — placebo starting at the randomization visit. There is no randomized evidence yet that gradually reducing a GLP-1 dose before stopping changes the regain trajectory. Clinical taper practices exist, but they are not evidence-graded the way the core efficacy data is.

It's Not Just the Pounds: Some Metabolic Improvements Can Reverse

Weight is the most visible outcome, but it is not the only one that moves after stopping. A post-hoc analysis of SURMOUNT-4 published in JAMA Internal Medicine in November 2025 (Horn et al.) examined how cardiometabolic markers shifted when tirzepatide was withdrawn — and found that reversal tracked closely with how much weight each patient regained. Participants who regained 75% or more of their lead-in loss saw blood pressure, HbA1c (a marker of longer-term blood sugar), lipid profiles, and waist circumference drift back toward pre-treatment levels. Patients who regained less weight retained more of their cardiometabolic improvement, even off the drug.

The direction of these findings is clinically meaningful: the cardiometabolic improvements many patients cite as a reason they wanted a GLP-1 — better blood sugar, lower blood pressure, improved triglycerides — do not appear to be a permanent "reset" of metabolic health. They track with sustained weight loss, which in most patients means continued treatment or an effective maintenance plan.

For patients using a GLP-1 under a cardiovascular-risk or sleep-apnea indication, this makes stopping a meaningfully different decision from stopping it for weight management. It is worth raising explicitly with your prescriber.

If You Have to Stop: Insurance, Cost, Shortage, or Side Effects

Not every decision to stop a GLP-1 is elective. The common real-world triggers in 2026:

Insurance or formulary change. Coverage for weight-management GLP-1s varies by plan and can shift at renewal, particularly for patients without a qualifying cardiovascular or sleep-apnea indication tied to their prescription.
Cost. High out-of-pocket costs are a common stop trigger. Manufacturer savings programs and direct-to-patient pharmacies exist for several GLP-1 products but do not apply to every patient or plan; a pharmacist or prescriber is usually the fastest path to identifying what is currently available for your product and coverage.
Shortage. The FDA maintains a public drug-shortage database listing current supply status for prescription drugs. Several semaglutide and tirzepatide products have had intermittent shortage listings since 2022; patients and prescribers should check the database for the current status of a specific formulation rather than rely on general impressions.
Side effects or tolerability. A minority of patients cannot stay on a GLP-1 because of persistent gastrointestinal symptoms, gallbladder events, or a contraindication that emerges during treatment. Our GLP-1 side effects overview covers the common adjustment period in more detail.

The FDA approved the first generic version of exenatide (the molecule in Byetta) in late 2024, per the FDA's 2024 First Generic Drug Approvals listing. A generic generally carries a lower price than its brand reference, but exenatide is a twice-daily short-acting agent with a materially different weight-loss profile from semaglutide or tirzepatide — it is context, not a direct substitute for modern weight-loss GLP-1s. Any medication swap during a GLP-1 gap is a prescriber-led decision, not a retail one.

Before You Stop: What to Discuss With Your Prescriber

The trials are withdrawal trials, not tapering trials. They do not establish an evidence-based way to "come off safely." But they do point to the questions worth asking a prescribing clinician before stopping — or before a forced pause:

Is this truly the time to stop? Some patients and prescribers reassess after a plateau and decide the current dose is still working as intended.
If the trigger is cost or insurance, are there alternatives? Direct-to-patient programs, manufacturer savings cards, or a switch to a different covered GLP-1 may narrow a coverage gap. Compounded GLP-1 products are not FDA-approved as identical substitutes for brand products and carry their own risks.
If the trigger is side effects, is a lower dose an option? Returning to a previous dose step, or slowing titration, sometimes resolves symptoms without stopping entirely.
What monitoring makes sense during a gap? Periodic weight checks, a follow-up A1C if diabetes is relevant, and blood-pressure readings can catch early drift and inform whether a restart or switch is appropriate.
What is the plan if weight begins to regain? A shared, written threshold for what would trigger a restart avoids a year-long delay between noticing regain and acting on it.

Having this conversation before stopping, not after, matters: patients who wait until they have regained meaningful weight to raise it often find insurance coverage harder to secure on the second pass.

Protecting Your Progress After You Stop

If you do stop — whether planned or forced — the evidence-based ways to minimize regain overlap with the strategies that matter during active GLP-1 treatment:

Maintain adequate protein intake. Reviews of protein and weight-loss maintenance support elevated protein intake to help preserve lean mass during and after a weight-loss phase, which in turn protects resting metabolic rate (Leidy et al., Am J Clin Nutr 2015). Specific daily targets — commonly cited around 1.2–1.6 g per kg of body weight in obesity-medicine practice — should be set with your prescriber or a registered dietitian, since the appropriate number depends on age, kidney function, and activity level.
Include resistance training. The Physical Activity Guidelines for Americans (2nd edition, 2018) recommend muscle-strengthening activities for all major muscle groups on at least 2 days per week for general health. Muscle lost during rapid weight loss is not reliably regained through cardio alone; even modest resistance work can slow sarcopenic drift.
Track the trajectory, not the daily number. A weekly or bi-weekly trend is more informative than any single weigh-in, which fluctuates with hydration and cycle.
Keep clinical monitoring routine. Blood pressure, A1C, and lipid markers can shift before weight does. Catching those trends early gives you and your prescriber more options.
Define your restart threshold in advance. An agreed-in-advance weight or health marker that would prompt restarting therapy turns a stopping decision into a reversible, monitored plan.

None of these replace the medication's hormonal effect. They create conditions where, if regain happens, it happens more slowly and is caught earlier.

When to Talk to Your Doctor

Reach out to your prescribing clinician if:

You are considering stopping for any reason, including cost or side effects.
You have already stopped and are noticing rapid regain (more than a pound or two per week, sustained for 2–4 weeks).
Your cardiometabolic markers — blood pressure, fasting glucose if you monitor it, or lipid results — have shifted in the weeks or months after stopping.
You are stopping abruptly because of a shortage or insurance gap and want to discuss alternatives.

Stopping a GLP-1 is rarely a simple "end of treatment" for patients who were prescribed one for obesity or a metabolic condition. It is a transition that deserves the same clinical attention the start of treatment received. See our medical disclaimer for the limits on what an article like this can offer as guidance.

GLP-1 Rebound Weight Gain: What Happens When You Stop?